#weight-loss

A phase 3b trial published in Nature Medicine found that daily oral orforglipron helped people maintain more of their prior weight loss after tirzepatide or semaglutide than placebo over 52 weeks.

A meta-analysis presented at the European Congress on Obesity suggests that roughly 8,500 daily steps may support long-term weight maintenance after dieting, addressing one of obesity treatment’s hardest problems.

A study announced by the 23andMe Research Institute identified genetic predictors tied to both GLP-1 weight-loss efficacy and side effects, highlighting a possible path toward more personalized obesity treatment.

A newly approved daily weight-loss pill moved through U.S. FDA review faster than most drugs in recent years, signaling continued momentum in the obesity treatment market.

After years of development challenges, oral GLP-1 weight loss drugs are finally hitting the market. Novo Nordisk's oral Wegovy is already available, with Eli Lilly's orforglipron expected to win FDA approval soon.

With one in eight American adults now taking GLP-1 medications like Ozempic and Wegovy, researchers at Georgia State University have uncovered why patients regain weight after stopping treatment — and a potential combination therapy that could solve the problem by targeting the brain's stress response system.

An oral compound from NTU Singapore reduces intestinal fat uptake and promotes beneficial gut bacteria without toxic side effects in animal models.

Researchers identify a naturally occurring gut molecule that reduces appetite and promotes fat burning without the side effects associated with current weight loss drugs.